# A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function

> **NCT05599997** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 32 (actual)

## Conditions studied

- Congestive Heart Failure
- Renal Impairment

## Interventions

- **DRUG:** Pecavaptan (BAY1753011)
- **DRUG:** Pecavaptan (BAY1753011)

## Key facts

- **NCT ID:** NCT05599997
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-25
- **Primary completion:** 2021-01-22
- **Final completion:** 2021-05-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05599997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05599997, "A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05599997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*